Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Antimuscarinic agent with atropine-like action. It is metabolized in Tolterodine
At latest update no published data on excretion into breast milk were found.
Until more published data on this drug in relation to breastfeeding is available, a known safer alternative as Tolterodine should be preferred with more favorable pharmacokinetics characteristics for lactation (e.g. high protein-binding capacity, faster elimination and lower oral bioavailability), particularly during the neonatal period and prematurity case.
Take as smallest dose as possible and avoid long-term use since anticholinergics can reduce milk production.
Monitoring anticholinergic symptoms in infants (dry mouth, constipation ..) is warranted.